{"success":true,"data":{"pressRelease":{"id":"167681","rtpr_id":"nGNX9dMW1K-20261013","ticker":"OPCH","exchange":"NASDAQ","all_tickers":["OPCH"],"title":"OPCH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Option Care Health to CD&R and McKesson","author":"Globe Newswire","published_at":"2026-10-13T13:00:03.253Z","article_body":"MONSEY, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl &\nFruchter LLP is investigating the fairness of the proposed sale of Option Care\nHealth, Inc. (NASDAQ: OPCH) (“OPCH”) to CD&R and McKesson Corporation for\n$32.05 per share in cash.\n\nNotably, the sale price is below the price targets for OPCH of at least two\nWall Street analysts before the sale was announced: A.J. Rice of UBS ($39.00\nper share) and Lisa Gill of J.P. Morgan ($33.00 per share) (Source: TipRanks).\n\nMoreover, on the Seeking Alpha investment website, shareholders expressed\ndisappointment with the sale price. One investor asserted, “Probably worth\nmore,” while another asked, “Was there a better deal to be had?”\n\nFinally, the $32.05 sale price is below OPCH’s 52-week high of $36.80, which\npotentially indicates an opportunistic purchase below fair value.\n\nIf you remain an OPCH shareholder and have concerns about the fairness of the\nproposed sale, you may contact our firm at the following link to discuss your\nlegal rights at no charge:\n\nhttps://wohlfruchter.com/cases/option-care-health/\n\nAlternatively, you may contact us by phone at 866-833-6245, or via email at\nalerts@wohlfruchter.com.\n\n“We are investigating whether the OPCH Board of Directors acted in the best\ninterests of OPCH shareholders in approving the sale,” explained Joshua\nFruchter, a founding partner of Wohl & Fruchter. “This includes whether the\ncash consideration agreed upon is fair to OPCH shareholders, and whether all\nmaterial information regarding the transaction has been fully disclosed. We\nencourage OPCH shareholders to contact us if they have any concerns.”\n\nAbout Wohl & Fruchter\nWohl & Fruchter LLP has for over a decade been representing investors in\nlitigation arising from fraud and other corporate misconduct, and has\nrecovered hundreds of millions of dollars in damages for investors. Please\nvisit our website, www.wohlfruchter.com, to learn more about our Firm, or\ncontact one of our partners.\n\nContact:\n\nWohl & Fruchter LLP\nJoshua E. Fruchter\nToll Free 866-833-6245\nalerts@wohlfruchter.com\nwww.wohlfruchter.com\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9dMW1K-20261013","title":"OPCH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Option Care Health to CD&R and McKesson","author":"Globe Newswire","ticker":"OPCH","created":"2026-10-13T13:00:03.253Z","tickers":["OPCH"],"exchange":"NASDAQ","article_body":"MONSEY, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl &\nFruchter LLP is investigating the fairness of the proposed sale of Option Care\nHealth, Inc. (NASDAQ: OPCH) (“OPCH”) to CD&R and McKesson Corporation for\n$32.05 per share in cash.\n\nNotably, the sale price is below the price targets for OPCH of at least two\nWall Street analysts before the sale was announced: A.J. Rice of UBS ($39.00\nper share) and Lisa Gill of J.P. Morgan ($33.00 per share) (Source: TipRanks).\n\nMoreover, on the Seeking Alpha investment website, shareholders expressed\ndisappointment with the sale price. One investor asserted, “Probably worth\nmore,” while another asked, “Was there a better deal to be had?”\n\nFinally, the $32.05 sale price is below OPCH’s 52-week high of $36.80, which\npotentially indicates an opportunistic purchase below fair value.\n\nIf you remain an OPCH shareholder and have concerns about the fairness of the\nproposed sale, you may contact our firm at the following link to discuss your\nlegal rights at no charge:\n\nhttps://wohlfruchter.com/cases/option-care-health/\n\nAlternatively, you may contact us by phone at 866-833-6245, or via email at\nalerts@wohlfruchter.com.\n\n“We are investigating whether the OPCH Board of Directors acted in the best\ninterests of OPCH shareholders in approving the sale,” explained Joshua\nFruchter, a founding partner of Wohl & Fruchter. “This includes whether the\ncash consideration agreed upon is fair to OPCH shareholders, and whether all\nmaterial information regarding the transaction has been fully disclosed. We\nencourage OPCH shareholders to contact us if they have any concerns.”\n\nAbout Wohl & Fruchter\nWohl & Fruchter LLP has for over a decade been representing investors in\nlitigation arising from fraud and other corporate misconduct, and has\nrecovered hundreds of millions of dollars in damages for investors. Please\nvisit our website, www.wohlfruchter.com, to learn more about our Firm, or\ncontact one of our partners.\n\nContact:\n\nWohl & Fruchter LLP\nJoshua E. Fruchter\nToll Free 866-833-6245\nalerts@wohlfruchter.com\nwww.wohlfruchter.com\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T13:00:04.213459114Z","server_sent_at_ms":1791896404213},"received_at":"2026-10-13T13:00:04.263Z","source_url":null},"analysis":{"id":"155969","press_release_id":"167681","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["take-private price below pre-deal analyst price targets and 52-week high, raising fairness concerns"],"eventType":"legal_litigation","narrative":"Wohl & Fruchter LLP is investigating the fairness of Option Care Health's proposed $32.05-per-share cash sale to CD&R and McKesson.\n\nThe firm notes the price is below pre-announcement analyst targets from UBS ($39.00) and J.P. Morgan ($33.00) and below OPCH's 52-week high of $36.80.\n\nThis is a law-firm solicitation seeking shareholder contacts, not a new disclosure from the issuer or a court action; the underlying merger remains the material event to monitor.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm fairness probe into OPCH take-private; suppress solicitation, track deal terms instead."},"keyFigures":{"dealValueUsd":0,"customDimensions":{"week_52_high":"$36.80","jpm_price_target":"$33.00","ubs_price_target":"$39.00","offer_price_per_share":"$32.05"}},"quotedText":"We are investigating whether the OPCH Board of Directors acted in the best interests of OPCH shareholders in approving the sale","namedEntities":{"people":[{"name":"Joshua Fruchter","role":"founding partner, Wohl & Fruchter LLP"},{"name":"A.J. Rice","role":"UBS analyst"},{"name":"Lisa Gill","role":"J.P. Morgan analyst"}],"products":[],"companies":[{"name":"Option Care Health, Inc.","ticker":"OPCH","relationship":"target of proposed sale"},{"name":"Wohl & Fruchter LLP","relationship":"plaintiff law firm"},{"name":"McKesson Corporation","relationship":"acquirer"},{"name":"CD&R","relationship":"acquirer"},{"name":"UBS","relationship":"analyst coverage firm"},{"name":"J.P. Morgan","relationship":"analyst coverage firm"}],"dollarAmounts":[{"amount":"$32.05 per share","context":"proposed cash sale price per OPCH share"},{"amount":"$39.00 per share","context":"UBS price target for OPCH"},{"amount":"$33.00 per share","context":"J.P. Morgan price target for OPCH"},{"amount":"$36.80","context":"OPCH 52-week high"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm investigation/solicitation notice, not an issuer disclosure, court action, or settlement. Note it relates to a pending take-private, but the release itself adds no new deal facts."},"tickerRelevance":{"others":[],"primary":"OPCH"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":["m_and_a"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingDealContext":true}},"event_type":"legal_litigation","event_type_secondary":["m_and_a"],"sentiment":"neutral","material_impact_score":1,"narrative":"Wohl & Fruchter LLP is investigating the fairness of Option Care Health's proposed $32.05-per-share cash sale to CD&R and McKesson.\n\nThe firm notes the price is below pre-announcement analyst targets from UBS ($39.00) and J.P. Morgan ($33.00) and below OPCH's 52-week high of $36.80.\n\nThis is a law-firm solicitation seeking shareholder contacts, not a new disclosure from the issuer or a court action; the underlying merger remains the material event to monitor.","key_figures":{"dealValueUsd":0,"customDimensions":{"week_52_high":"$36.80","jpm_price_target":"$33.00","ubs_price_target":"$39.00","offer_price_per_share":"$32.05"}},"named_entities":{"people":[{"name":"Joshua Fruchter","role":"founding partner, Wohl & Fruchter LLP"},{"name":"A.J. Rice","role":"UBS analyst"},{"name":"Lisa Gill","role":"J.P. Morgan analyst"}],"products":[],"companies":[{"name":"Option Care Health, Inc.","ticker":"OPCH","relationship":"target of proposed sale"},{"name":"Wohl & Fruchter LLP","relationship":"plaintiff law firm"},{"name":"McKesson Corporation","relationship":"acquirer"},{"name":"CD&R","relationship":"acquirer"},{"name":"UBS","relationship":"analyst coverage firm"},{"name":"J.P. Morgan","relationship":"analyst coverage firm"}],"dollarAmounts":[{"amount":"$32.05 per share","context":"proposed cash sale price per OPCH share"},{"amount":"$39.00 per share","context":"UBS price target for OPCH"},{"amount":"$33.00 per share","context":"J.P. Morgan price target for OPCH"},{"amount":"$36.80","context":"OPCH 52-week high"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T13:00:19.729Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingDealContext":true}},"durationMs":5532,"modelName":"glm-5.3-flashx"}}